Sarah Sharman Moser
Overview
Explore the profile of Sarah Sharman Moser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sharman Moser S, Spectre G, Raanani P, Friedman-Mazursky O, Tirosh M, Chodick G, et al.
Res Pract Thromb Haemost
. 2022 May;
6(4):e12653.
PMID: 35619639
Background: Recent international guidelines recommend thromboprophylaxis in patients with cancer at intermediate-high venous thromboembolism (VTE) risk. Objectives: We aimed to assess the current incidence, risk factors and management of cancer-associated...
12.
Sharman Moser S, Yaari S, Urban D, Apter L, Passwell N, Teper G, et al.
Cancer Epidemiol
. 2022 May;
79:102156.
PMID: 35594797
Background: Health-care providers in the US revealed that a substantial proportion of mNSCLC patients do not receive any first-line therapy and the biggest gaps in care are time inefficiencies in...
13.
Sharman Moser S, Chodick G, Ni Y, Chalothorn D, Wang M, Shuldiner A, et al.
Thromb Haemost
. 2021 Sep;
122(5):808-817.
PMID: 34555861
The objective of this study was to assess the relationship between factor XI (FXI) deficiency and the risks of bleeding and cardiovascular (CV) events. We conducted a retrospective cohort study...
14.
Sharman Moser S, Apter L, Arunachalam A, Burke T, Shalev V, Chodick G, et al.
Immunotherapy
. 2021 May;
13(10):851-861.
PMID: 34034511
We describe PD-L1 testing patterns and first-line treatment for patients with metastatic non-small-cell lung cancer in a 2.3 million-member state-mandated health service in Israel. Newly diagnosed stage IV non-small-cell lung...
15.
Sharman Moser S, Bar J, Kan I, Ofek K, Cohen R, Khandelwal N, et al.
Curr Oncol
. 2021 Jan;
28(1):317-331.
PMID: 33435584
In this observational study, we assessed treatment patterns and prognostic factors in patients with small cell lung cancer (SCLC) in a large state-mandated healthcare organization in Israel. All incident cases...
16.
Sharman Moser S, Rabinovitch M, Rotem R, Koren G, Shalev V, Chodick G
BMJ Nutr Prev Health
. 2020 Nov;
2(1):30-34.
PMID: 33235954
Objective: Folic acid (FA) supplementation has long been recommended before and during pregnancy to reduce the risk of neural tube defects. Factors influencing adherence to FA supplementation have been extensively...
17.
Sharman Moser S, Chodick G, Bar-On S, Shalev V
Int J Womens Health
. 2020 Jul;
12:445-454.
PMID: 32606996
Objective: Self-reported studies estimated that as many as 50-75% of women experience symptoms during menopause; however, limited real-world clinical data are available to support this observation. The electronic databases of...
18.
Weil C, Gelerstein S, Sharman Moser S, Chodick G, Barit Ben-David N, Shalev V, et al.
Leuk Res
. 2019 Sep;
85:106219.
PMID: 31473468
Background: Survival of patients with multiple myeloma (MM) has improved significantly with access to autologous stem cell transplant (SCT) and new treatments. This study aims to describe epidemiology, treatment patterns,...
19.
Koren G, Sharman Moser S
Med Hypotheses
. 2019 Aug;
132:109350.
PMID: 31421417
There has been a dramatic increase in the incidence of autism spectrum disorder (ASD) in recent decades but the causes have not been elucidated. To date, numerous studies have shown...
20.
Sharman Moser S, Davidovitch M, Rotem R, Chodick G, Shalev V, Koren G
Reprod Toxicol
. 2019 Aug;
89:173-177.
PMID: 31376478
Objective: To examine whether there is an association between the cumulative dose of folic acid (FA) purchased by mothers, and risk of autistic spectrum disorders (ASD) in their progeny. Methods:...